171 related articles for article (PubMed ID: 37474097)
1. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies.
Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF
Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097
[TBL] [Abstract][Full Text] [Related]
2. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
Snodin DJ
Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
[TBL] [Abstract][Full Text] [Related]
3. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
4. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
5. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J
Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841
[TBL] [Abstract][Full Text] [Related]
6. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
7. Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis.
Ellis P; Kenyon M; Dobo K
Regul Toxicol Pharmacol; 2013 Mar; 65(2):201-13. PubMed ID: 23228434
[TBL] [Abstract][Full Text] [Related]
8. Mutagenic impurities in pharmaceuticals: a critique of the derivation of the cancer TTC (Threshold of Toxicological Concern) and recommendations for structural-class-based limits.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2013 Nov; 67(2):299-316. PubMed ID: 23988886
[TBL] [Abstract][Full Text] [Related]
9. A deep dive into historical Ames study data for N-nitrosamine compounds.
Tennant RE; Ponting DJ; Thresher A
Regul Toxicol Pharmacol; 2023 Sep; 143():105460. PubMed ID: 37495012
[TBL] [Abstract][Full Text] [Related]
10. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
11. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage.
Fine J; Allain L; Schlingemann J; Ponting DJ; Thomas R; Johnson GE
Regul Toxicol Pharmacol; 2023 Dec; 145():105505. PubMed ID: 37805106
[TBL] [Abstract][Full Text] [Related]
12. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
13. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
14. Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs).
Bercu JP; Masuda-Herrera M; Trejo-Martin A; Sura P; Jolly R; Kenyon M; Thomas R; Ponting DJ; Snodin D; Tuschl G; Simon S; De Vlieger K; Hutchinson R; Czich A; Glowienke S; Reddy MV; Johanssen S; Vock E; Claude N; Weaver RJ
Regul Toxicol Pharmacol; 2023 Aug; 142():105415. PubMed ID: 37257751
[TBL] [Abstract][Full Text] [Related]
15. Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of
Chakravarti S
Chem Res Toxicol; 2023 Jun; 36(6):959-970. PubMed ID: 37267457
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
17. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.
Tchernev G; Kordeva S
Georgian Med News; 2023 Apr; (337):63-67. PubMed ID: 37354675
[TBL] [Abstract][Full Text] [Related]
18. Quantum Mechanical Assessment of Nitrosamine Potency.
De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
[TBL] [Abstract][Full Text] [Related]
19. Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
Bercu JP; Galloway SM; Parris P; Teasdale A; Masuda-Herrera M; Dobo K; Heard P; Kenyon M; Nicolette J; Vock E; Ku W; Harvey J; White A; Glowienke S; Martin EA; Custer L; Jolly RA; Thybaud V
Regul Toxicol Pharmacol; 2018 Apr; 94():172-182. PubMed ID: 29408293
[TBL] [Abstract][Full Text] [Related]
20. Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).
Bercu JP; Masuda-Herrera M; Johnson G; Czich A; Glowienke S; Kenyon M; Thomas R; Ponting DJ; White A; Cross K; Waechter F; Rodrigues MAC
Regul Toxicol Pharmacol; 2021 Jul; 123():104926. PubMed ID: 33862169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
